High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery

Annals of Thoracic Surgery

Volumn 75, Issue 2, 2003, Pages 430-437

  Mössinger, Hansjörg ^a,b   Dietrich, Wulf ^a   Braun, Siegmund L ^a   Jochum, Marianne ^a   Meisner, Hans ^a   Richter, Josef A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3A; CYTOKINE; D DIMER; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PROTHROMBIN;

ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SURGERY; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FALLOT TETRALOGY; GREAT VESSELS TRANSPOSITION; HEART ATRIUM SEPTUM DEFECT; HEMOSTASIS; HUMAN; INFANT; INFLAMMATION; MAJOR CLINICAL STUDY; PEDIATRIC SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE FUNCTION;

APROTININ; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HEART DEFECTS, CONGENITAL; HEMOSTASIS; HUMANS; INFANT; INTERLEUKINS; OXYGENATORS, MEMBRANE; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; TIME FACTORS;

EID: 0037314646     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(02)04412-0     Document Type: Article

References (22)

1. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-7.
2. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg 1997;85:1258-67.
3. Mössinger H, Dietrich W. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Ann Thorac Surg 1998;65(Suppl):45-50.
4. Davies MJ, Allen A, Kort H, et al. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Ann Thorac Surg 1997;63:497-503.
5. DErrico CC, Shayevitz JR, Martindale SJ, Mosca RS, Bove EL. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 1996;83:1193-9.
6. Royston D, Taylor KM, Bidstrup BP, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;ii:1289-91.
7. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 1993;105:712-20.
8. Seghaye MC, Duchateau J, Grabitz RG, et al. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. Ann Thorac Surg 1996;61:1205-11.
9. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995;110:1658-62.
10. Müller-Esterl W, Oettl A, Truscheit E, Fritz H. Monitoring of aprotinin plasma levels by an enzyme-linked immunosorbent assay (ELISA). Fresenius Z Anal Chem 1984;317:718-22.
11. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996;93:229-37.
12. Carrel TP, Schwanda M, Vogt PR, Turina MI. Aprotinin in pediatric cardiac operations: A benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998;66:153-8.
13. Royston D, Cardigan R, Gippner-Steppert C, Jochum M. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen? Anesth Analg 2001;92:830-6.
14. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation pattern in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-26.
15. Petaja J, Peltola K, Sairanen H, et al. Fibrinolysis, antithrombin III, and protein c in neonates during cardiac operations. J Thorac Cardiovasc Surg 1996;112:665-71.
16. Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC, Taylor KM. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2000;69:1192-7.
17. Ashraf S, Tian Y, Cowan D, et al. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release. Ann Thorac Surg 1997;63:68-73.
18. Hill GE, Springall DR, Robbins RA. Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass. Surgery 1997;121:449-55.
19. Rahman A, Ustunda B, Burma O, Ozercan IH, Cekirdekci A, Bayar MK. Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass? Eur J Cardiothorac Surg 2000;18:583-8.
20. Wippermann CF, Schmid FX, Eberle B, et al. Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. Ann Thorac Surg 1999;67:173-6.
21. Miller BE, Tosone SR, Tam VKH, et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 1998;66:535-40.
22. Dietrich W, Späth P, Zühlsdorf M, et al. Anaphylactic reactions to aprotinin reexposure in cardiac surgery-relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiology 2001;95:64-71.